The goal of this activity is for learners to better understand of AD immunopathology and the mechanisms of action (MoAs) of and clinical data on new drugs in development that target the OX40-OX40L pathway.
- Provider:Medscape, LLC
- Activity Link: https://www.medscape.org/viewarticle/1001214
- Start Date: 2024-06-26 05:00:00
- End Date: 2024-06-26 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
- Commercial Support: Source: Sanofi - Amount: 231500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest